Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xoma/Ingene merger

Executive Summary

There is "absolutely no reason whatsoever that [Ingene's previous R&D agreement with NeoRx] will create any complication" in the proposed merger with Xoma, an Ingene spokesperson said in response to a story on the merger in the Aug. 14 issue of "The Pink Sheet" (T&G-1). "There is no expectation that any of Ingene's previous arrangements will cause any difficulty with the merger," Xoma said. "The Pink Sheet" had stated that Ingene's arrangement with NeoRx "complicates" the merger. According to Ingene, the NeoRx deal announced in April 1988 gives NeoRx "exclusive worldwide rights to products which contain the chimeric antibodies developed from NeoRx's mouse monoclonals".
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel